FDA's Overreach on Compounded Peptides The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not Dihexa for Women: Cognitive and Hormonal Health Benefits DIHEXA Research Capsules Peptide Tech A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are